Skip to content
COVID-19 / SPECIALTY RESEARCH

OphthalmologyIn perspective.

The key COVID-19 findings in ophthalmology, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.

INSIDE THIS MONITOR
30cited sources
4available findings

Study findings updated

AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.

THE SHORT VERSION

What’s worth knowing.

The key findings, what they mean, and the context that matters.

THE HEADLINE TAKEAWAY11-36%

Eye manifestations were reported in 11-36% of COVID-19 patients

A systematic review and meta-analysis reported ocular manifestations in 11-36% of patients with COVID-19, ranging from conjunctivitis to retinal vascular changes.

This broad outcome combines different eye conditions; their timing, severity, and individual frequencies are not available in this summary.

See the evidence

of COVID-19 patients develop ocular manifestations

11-36%

Nasiri N, et al. Ocular Manifestations of COVID-19: A Systematic Review and Meta-analysis. J Ophthalmic Vis Res. 2021;16(1):103-112.

02

Retinal vein occlusion risk increased after COVID-19

A self-controlled case series reported increased retinal vein occlusion risk after COVID-19.

The reference period used for comparison and the risk window are not available in this summary, so the reported hazard magnitude is not displayed.

See the evidence

Retinal Vein Occlusion

+35%
HR 1.35 (95% CI: 1.12-1.62)

Hashemi N, et al. Risk of retinal vein occlusion after COVID-19: A self-controlled case series study. J Stroke Cerebrovasc Dis. 2022;31(8):106590.

03

Retinal nerve fiber layer thinning was reported in recovered COVID-19 patients

15-30%

The study reported retinal nerve fiber layer thinning in 15-30% of recovered COVID-19 patients on optic nerve and macular optical coherence tomography.

The finding applies to the recovered patients studied. Timing, visual impact, and any comparison group are not available in this summary.

See the evidence

RNFL Thinning

15-30%
Prevalence in recovered patients

Burgos-Blasco B, et al. Optic nerve and macular optical coherence tomography in recovered COVID-19 patients. Eur J Ophthalmol. 2021;31(6):2948-2954.

04

Review reported reduced retinal vessel density in COVID-19

A systematic review of optical coherence tomography angiography findings in COVID-19 reported reduced retinal vessel density.

The patient setting and reference group are not available in this summary, so the percentage reduction is not displayed.

See the evidence

Retinal Vessel Density

-8-15%
Significant reduction on OCT-A

Abrishami M, et al. Optical coherence tomography angiography findings in COVID-19: A systematic review. Can J Ophthalmol. 2021;56(6):361-369.

Study-specific findings. Different populations, treatments and follow-up periods can produce different results.

THE RESEARCH, AS IT ARRIVES

Latest studies.

The newest findings added to this collection.
The learning from each, already distilled.

Study summaries are not available in this collection yet. The original evidence remains accessible in each monitor.

Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.

WHEN YOU WANT TO GO DEEPER
See all 4 findingsOriginal results, comparisons and study details.
4 of 4 source groupsFindings stay together with their study.
SOURCE 051 finding

Abrishami M, et al. Optical coherence tomography angiography findings in COVID-19: A systematic review. Can J Ophthalmol. 2021;56(6):361-369.

Original source link unavailableView citation [5]

Retinal Vessel Density

-8-15%Significant reduction on OCT-ASource [5]
SOURCE 101 finding

Burgos-Blasco B, et al. Optic nerve and macular optical coherence tomography in recovered COVID-19 patients. Eur J Ophthalmol. 2021;31(6):2948-2954.

Original source link unavailableView citation [10]

RNFL Thinning

15-30%Prevalence in recovered patientsSource [10]
SOURCE 161 finding

Kaulen LD, et al. Neurological complications of COVID-19 and COVID-19 vaccines: A population-based study. J Neurol. 2022;269(11):5987-5999.

Original source link unavailableView citation [16]

Optic Neuritis

+56%HR 1.56 (95% CI: 1.27-1.91)Source [16]
SOURCE 171 finding

Hashemi N, et al. Risk of retinal vein occlusion after COVID-19: A self-controlled case series study. J Stroke Cerebrovasc Dis. 2022;31(8):106590.

Original source link unavailableView citation [17]

Retinal Vein Occlusion

+35%HR 1.35 (95% CI: 1.12-1.62)Source [17]
Browse the 30 original sourcesThe complete bibliography behind this monitor.
  1. [1]

    Nasiri N, et al. Ocular Manifestations of COVID-19: A Systematic Review and Meta-analysis. J Ophthalmic Vis Res. 2021;16(1):103-112.

    Open original source in a new tab
  2. [2]

    Zhong Y, et al. Ocular manifestations in COVID-19 patients: A systematic review and meta-analysis. Travel Med Infect Dis. 2021;44:102191.

    Open original source in a new tab
  3. [3]

    Aiello F, et al. Coronavirus disease 2019 (COVID-19) and eye: A review of ophthalmic manifestations of COVID-19. Eur J Ophthalmol. 2022;32(3):1385-1403.

    Original source link unavailable
  4. [4]

    Finsterer J, et al. COVID-19-associated cranial nerve neuropathy: A systematic review. Bosn J Basic Med Sci. 2021;21(5):525-531.

    Original source link unavailable
  5. [5]

    Abrishami M, et al. Optical coherence tomography angiography findings in COVID-19: A systematic review. Can J Ophthalmol. 2021;56(6):361-369.

    Original source link unavailable
  6. [6]

    Invernizzi A, et al. Retinal findings in patients with COVID-19: Results from the SERPICO-19 study. EClinicalMedicine. 2020;27:100550.

    Original source link unavailable
  7. [7]

    Wu P, et al. Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020;138(5):575-578.

    Original source link unavailable
  8. [8]

    Marinho PM, et al. Retinal findings in patients with COVID-19. Lancet. 2020;395(10237):1610.

    Original source link unavailable
  9. [9]

    Savastano A, et al. Detection of SARS-CoV-2 in the retina and assessment of retinal changes after COVID-19. Ophthalmol Retina. 2021;5(12):1256-1263.

    Original source link unavailable
  10. [10]

    Burgos-Blasco B, et al. Optic nerve and macular optical coherence tomography in recovered COVID-19 patients. Eur J Ophthalmol. 2021;31(6):2948-2954.

    Original source link unavailable
  11. [11]

    Landecho MF, et al. COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease? J Intern Med. 2021;289(1):116-120.

    Original source link unavailable
  12. [12]

    Turker IC, et al. Optical coherence tomography angiography findings in patients with COVID-19. Can J Ophthalmol. 2021;56(2):83-87.

    Original source link unavailable
  13. [13]

    Dinkin M, et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology. 2020;95(5):221-223.

    Original source link unavailable
  14. [14]

    Bettach E, et al. COVID-19-associated uveitis: A case series and review of the literature. Rheumatology. 2021;60(SI):SI29-SI36.

    Original source link unavailable
  15. [15]

    Virgo J, et al. Acute macular neuroretinopathy following COVID-19 infection. Eye (Lond). 2020;34(12):2163-2165.

    Original source link unavailable
  16. [16]

    Kaulen LD, et al. Neurological complications of COVID-19 and COVID-19 vaccines: A population-based study. J Neurol. 2022;269(11):5987-5999.

    Original source link unavailable
  17. [17]

    Hashemi N, et al. Risk of retinal vein occlusion after COVID-19: A self-controlled case series study. J Stroke Cerebrovasc Dis. 2022;31(8):106590.

    Original source link unavailable
  18. [18]

    Al-Aly Z, et al. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022;28(11):2398-2405.

    Original source link unavailable
  19. [19]

    Davis HE, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146.

    Original source link unavailable
  20. [20]

    Gambini G, et al. Ocular surface impairment after COVID-19. Cornea. 2021;40(11):1454-1460.

    Original source link unavailable
  21. [21]

    Inomata T, et al. Association between dry eye disease and COVID-19. Ophthalmol Ther. 2022;11(1):67-80.

    Original source link unavailable
  22. [22]

    Sen M, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India. Lancet Infect Dis. 2021;21(12):1636-1644.

    Original source link unavailable
  23. [23]

    Xia J, et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020;92(6):589-594.

    Original source link unavailable
  24. [24]

    Kumar K, et al. SARS-CoV-2 detection in the ocular surface: A systematic review. BMJ Open Ophthalmol. 2020;5(1):e000574.

    Original source link unavailable
  25. [25]

    Guan WJ, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.

    Original source link unavailable
  26. [26]

    Sen S, et al. Neuro-ophthalmological manifestations of COVID-19: A review. Curr Eye Res. 2021;46(8):1103-1115.

    Original source link unavailable
  27. [27]

    Dumitrascu OM, et al. Acute ophthalmic artery occlusion in a COVID-19 patient. J Stroke Cerebrovasc Dis. 2020;29(8):104870.

    Original source link unavailable
  28. [28]

    Pirraglia MP, et al. Retinal involvement and ocular findings in COVID-19 pneumonia patients. Sci Rep. 2020;10(1):17419.

    Original source link unavailable
  29. [29]

    Casagrande M, et al. Detection of SARS-CoV-2 genomic and subgenomic RNA in retina and optic nerve of patients with COVID-19. Br J Ophthalmol. 2022;106(9):1313-1317.

    Original source link unavailable
  30. [30]

    Hu K, et al. Ophthalmic manifestations of coronavirus (COVID-19). StatPearls [Internet]. Updated 2023.

    Original source link unavailable
ABOUT THIS MONITOR

Understanding includes the limits.

This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.

Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.

KEEP YOUR QUESTIONS CLOSE

A little more understanding.
Wherever you are.

Explore the ModernDoc app